ES2196213T3 - Derivados de benzoxazoles como activadores parciales del receptor de serotonina 5-ht3. - Google Patents

Derivados de benzoxazoles como activadores parciales del receptor de serotonina 5-ht3.

Info

Publication number
ES2196213T3
ES2196213T3 ES97107580T ES97107580T ES2196213T3 ES 2196213 T3 ES2196213 T3 ES 2196213T3 ES 97107580 T ES97107580 T ES 97107580T ES 97107580 T ES97107580 T ES 97107580T ES 2196213 T3 ES2196213 T3 ES 2196213T3
Authority
ES
Spain
Prior art keywords
group
serotonine
receiver
sub
replaced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97107580T
Other languages
English (en)
Inventor
Yasuo Sato
Megumi Yamada
Kazuko Kobayashi
Katsuyoshi Iwamatsu
Fukio Konno
Koichi Shudo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Meiji Seika Kaisha Ltd
Original Assignee
Meiji Seika Kaisha Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Seika Kaisha Ltd filed Critical Meiji Seika Kaisha Ltd
Application granted granted Critical
Publication of ES2196213T3 publication Critical patent/ES2196213T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

ESTA INVENCION PROPORCIONA UN ACTIVADOR PARCIAL DEL RECEPTOR DE SEROTONINA 5 PTOR DE SEROTONINA 5 TOR DE SEROTONINA 5 TO SECUNDARIO. EN PARTICULAR, SOBRE LA BASE DEL HALLAZGO DE QUE DERIVADOS DE BENZOXAZOL RECIENTEMENTE SINTETIZADOS TIPIFICADOS POR LOS COMPUESTOS DE FORMULA SIGUIENTE (2) TIENEN ACCION ANTAGONISTA INTENSA DEL RECEPTOR DE SEROTONINA 5-HT3 Y ACTIVADORA DEL RECEPTOR 5 OS DE BENZOXAZOL COMO ACTIVADORES PARCIALES DEL RECEPTOR DE SEROTONINA 5 PUEDEN SER IGUALES O DIFERENTES UNO DE OTRO Y CADA UNO REPRESENTA UN ATOMO DE HIDROGENO, UN ATOMO DE HALOGENO, UN GRUPO ALQUILO INFERIOR SUSTITUIDO O NO, UN GRUPO ALQUENILO INFERIOR SUSTITUIDO O NO, O UN GRUPO AMINO SUSTITUIDO O NO, O DOS GRUPOS R{SUB,1} Y R{SUB,2} PUEDEN ESTAR UNIDOS PARA FORMAR UNA ESTRUCTURA EN ANILLO, A SABER UN ANILLO DE BENCENO; R{SUB,5} REPRESENTA UN ATOMO DE HIDROGENO, UN GRUPO ALQUILO INFERIOR SUSTITUIDO O NO O UN GRUPO ALQUENILO INFERIOR SUSTITUIDO O NO; Y M ES UN NUMERO ENTERO DE 1 A 4.
ES97107580T 1996-05-09 1997-05-07 Derivados de benzoxazoles como activadores parciales del receptor de serotonina 5-ht3. Expired - Lifetime ES2196213T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP11500896 1996-05-09
JP09382197A JP3520177B2 (ja) 1996-05-09 1997-04-11 セロトニン５−ｈｔ３受容体部分活性薬

Publications (1)

Publication Number Publication Date
ES2196213T3 true ES2196213T3 (es) 2003-12-16

Family

ID=26435106

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97107580T Expired - Lifetime ES2196213T3 (es) 1996-05-09 1997-05-07 Derivados de benzoxazoles como activadores parciales del receptor de serotonina 5-ht3.

Country Status (6)

Country Link
US (5) US6037342A (es)
EP (1) EP0806419B1 (es)
JP (1) JP3520177B2 (es)
KR (1) KR100426981B1 (es)
DE (1) DE69720317T2 (es)
ES (1) ES2196213T3 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3520177B2 (ja) * 1996-05-09 2004-04-19 明治製菓株式会社 セロトニン５−ｈｔ３受容体部分活性薬
TW520370B (en) * 1998-11-20 2003-02-11 Meiji Seika Kaisha Benzooxazole derivatives and a pharmaceutical composition containing the derivatives as an active ingredient
CA2452596C (en) * 2001-07-05 2010-12-21 Takeda Chemical Industries, Ltd. Benzo-fused 5-membered heterocyclic compounds, their production and use
US6861533B2 (en) 2001-11-23 2005-03-01 Irm Llc Solution phase sythesis of arylbenzoxazoles
KR100544126B1 (ko) * 2003-08-26 2006-01-23 삼성에스디아이 주식회사 유기 전계 발광 소자 및 그 제조방법
WO2006022194A1 (en) * 2004-08-23 2006-03-02 Semiconductor Energy Laboratory Co., Ltd. Electron injecting composition, and light emitting element and light emitting device using the electron injecting composition
EP1798227A4 (en) * 2004-09-09 2009-09-09 Res Found Itsuu Lab SEROTONIN 5-HT3 RECEPTOR AGONIST
US7771601B1 (en) * 2005-11-14 2010-08-10 Shepherd Samuel L Treatment of waste sludge with recycling
AU2007229492B2 (en) 2006-03-28 2011-11-03 High Point Pharmaceuticals, Llc Benzothiazoles having histamine H3 receptor activity
WO2015005429A1 (ja) 2013-07-10 2015-01-15 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 新規ｐｄｅ４阻害剤
CN110114358B (zh) * 2016-12-26 2021-12-03 明治制果药业株式会社 新的化合物以及其药理学上所容许的盐
JP6815566B2 (ja) 2018-06-27 2021-01-20 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 炎症性疾患、自己免疫疾患、線維化疾患、及びがん疾患の治療剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1228524A (es) * 1958-05-23 1960-08-31
SU417421A1 (es) * 1972-01-10 1974-02-28
ES2038532B1 (es) * 1991-05-10 1994-02-16 Espanola Prod Quimicos Procedimiento de preparacion de nuevos derivados de 2-piperacinilbecimidazol.
JP3193560B2 (ja) * 1993-04-16 2001-07-30 明治製菓株式会社 新規ベンゾオキサゾール誘導体
CO4520280A1 (es) * 1993-10-26 1997-10-15 Boehringer Ingelheim Pharma Derivados de pirrolidina, inhibidores de la bioscientesis de leucotrienos
JP3520177B2 (ja) * 1996-05-09 2004-04-19 明治製菓株式会社 セロトニン５−ｈｔ３受容体部分活性薬
KR100901648B1 (ko) * 2002-06-29 2009-06-09 매그나칩 반도체 유한회사 반도체 소자의 제조 방법

Also Published As

Publication number Publication date
JPH1029987A (ja) 1998-02-03
KR19980079226A (ko) 1998-11-25
DE69720317D1 (de) 2003-05-08
US6552057B2 (en) 2003-04-22
US6867226B2 (en) 2005-03-15
DE69720317T2 (de) 2004-02-19
US6297246B1 (en) 2001-10-02
US6333328B1 (en) 2001-12-25
EP0806419B1 (en) 2003-04-02
EP0806419A1 (en) 1997-11-12
US20010016579A1 (en) 2001-08-23
US6037342A (en) 2000-03-14
JP3520177B2 (ja) 2004-04-19
US20030013730A1 (en) 2003-01-16
KR100426981B1 (ko) 2004-09-01

Similar Documents

Publication Publication Date Title
ES2159839T3 (es) Derivados del propano, su preparacion y su uso.
ES2196213T3 (es) Derivados de benzoxazoles como activadores parciales del receptor de serotonina 5-ht3.
ES2123829T3 (es) Derivados de 3-(5-tetrazolil-bencil)amino-piperidina y antagonistas de las taquiquininas.
ES2100187T3 (es) Derivados de carboestirilos y composiciones farmaceuticas que los contienen.
AR005706A1 (es) Inhibidores egfr de 4-aminoquinzolina, procedimiento para su obtencion, composicion farmaceutica que los contiene, uso de los mismos para lapreparacion de un medicamento util como agente antineoplasico
PE20040935A1 (es) Analogos de 2-quinazolina sustituida-4-ilamina como moduladores de los receptores de capsaicina
AR005166A1 (es) Compuestos de quinolina y quinazolina, su uso, un procedimiento para producirlos, formulaciones farmaceuticas que los incluyen y compuesto utilescomo intermedios en dicho procedimiento.
CO5630036A2 (es) Nuevos derivados indol con afinidad por el receptor 5-ht6
ES2075082T3 (es) Derivados de isoquinolina para el tratamiento del glaucoma o hipertension ocular.
ES2191838T3 (es) Derivados de tetrahidroisoquinoleina como moduladores de los receptores d3 de la dopamina.
AR029301A1 (es) Compuestos derivados de biarilo, metodos para su preparacion composiciones que los contienen, su uso como agonistas en receptores beta-adreno-receptores atipicos
ES2059327T3 (es) Derivados de tetrahidronaftaleno y de indano, obtencion de los mismos y utilizacion en preparados farmaceuticos.
ES2052675T3 (es) 3-(4-piperazinil-sustituido en 1)butil)-4-tiazolidinonas, un procedimiento para su preparacion y su uso como medicamentos.
BR0007595A (pt) 4-(heterociclisulfonamido)-5-metóxi-6-(2-metoxifenó xi)-2-fenil-ou piridilpirimidinas como antagonistas de receptor de endotelina
AR035153A1 (es) Derivados de carboxamidas y cetonas de dihidrobenzodioxina
PE20020346A1 (es) Derivados de fenoxibencilamina como ssri
CO4340623A1 (es) Derivados de indolina, metodo de preparacion y uso
ES2175089T3 (es) Una combinacion de un inhibidor de la absorcion de 5 - ht con un ant agonista selectivo de 5 ht1a.
ES2160106T3 (es) Derivados de la quinazolina.
ES2038678T3 (es) Procedimiento para la preparacion de n-(2-alquil-3-mercapto-glutaril)-alfamino-acidos.
ES2154470T3 (es) Derivados de tetrahidroisoquinolina y su uso farmaceutico.
ES2067874T3 (es) Derivados de acetamida.
ES2117339T3 (es) Nuevos derivados de polivinilamina, materiales soporte a base de aluminio revestidos con estos derivados, asi como su empleo para la obtencion de planchas offset.
ES2128668T3 (es) Agonistas del receptor de 5-ht4.
ES2154605B1 (es) Nuevos derivados mixtos de bencimidazol-arilpiperazina con afinidad por los receptores serotoninergicos 5-ht1a y 5-ht3